tervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial [J]. J Interv Cardiol, 2011, 24(2): 105-111.

[3] Gu Y L, Kampinga M A, Wieringa W G, *et al*. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: The comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial [J]. Circulation, 2010, 122(25): 2709-2717.

[4] Dominguez-Rodriguez A, Abreu-Gonzalez P, Avanzas P, *et al*. Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations [J]. Atherosclerosis, 2009, 206(2): 523-527.

[5] Higgins J P T, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5. 1. 0 [M]. The Cochrane Collaboration, 2011.

[6] Bertrand O F, Rodes-cabau J, Larose E, *et al*. Intracoronary compared to intravenous Abciximab and high-dose bolus compared to standard dose in patients with ST-segment elevation myocardial infarction undergoing transradial primary percutaneous coronary intervention: a two-by-two factorial placebo-controlled randomized study [J]. Am J Cardiol, 2010, 105(11): 1520-1527.

[7] Thiele H, Schindler K, Friedenberger J, *et al*. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial [J]. Circulation, 2008, 118 (1): 49-57.

[8] Bellandi F, Maioli M, Gallopin M, *et al*. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention [J]. Catheter Cardiovasc Interv, 2004, 62(2): 186-192.

[9] 陈少源, 方红域, 谢培益, 等. 冠脉内使用替罗非班治疗ST段抬高型心肌梗死的临床观察 [J]. 世界临床药物, 2010, 31(4): 233-236, 244.

[10] 金光临, 刘幼文, 左辉华, 等. 急性心肌梗死直接PCI冠脉内注射替罗非班预防无复流 [J]. 中山大学学报: 医学科学版, 2009, 30(A03): 185-188, 194.

[11] 高航, 孔敬博, 黄广勇, 等. 冠状动脉内应用替罗非班对急性ST段抬高型心肌梗死急诊介入治疗的疗效和安全性 [J]. 山东医药, 2008, 48(26): 54-55.

[12] 李志娟, 张薇, 董平栓, 等. 急性心肌梗死患者介入术中冠脉内应用替罗非班的疗效和安全性评价 [J]. 陕西医学杂志, 2008, 37(4): 425-427.

[13] 杨新春, 张大鹏, 王乐丰, 等. 冠状动脉内应用国产替罗非班对急性ST段抬高心肌梗死急诊介入治疗后心肌灌注和临床预后的影响 [J]. 中华心血管病杂志, 2007, 35(6): 517-522.

[14] Eitel I, Friedenberger J, Fuernau G, *et al*. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i. v. versus i. c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI) [J]. Clin Res Cardiol, 2011, 100(5): 425-432.

[15] Hansen P R, Iversen A, Abdulla J. Improved clinical outcomes with intracoronary compared to intravenous abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a systematic review and meta-analysis [J]. J Invasive Cardiol, 2010, 22(6): 278-282.

[16] De-Luca G, Ucci G, Cassetti E, *et al*. Benefits from small molecule administration as compared with abciximab among patients with ST-segment elevation myocardial infarction treated with primary angioplasty: a meta-analysis [J]. J Am Coll Cardiol, 2009, 53(18): 1668-1673.

[17] De-Luca G, Gibson C M, Bellandi F, *et al*. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis [J]. Heart, 2008, 94(12): 1548-1558.

[18] Stone G W, Witzenbichler B, Guagliumi G, *et al*. Bivalirudin during primary PCI in acute myocardial infarction [J]. N Engl J Med, 2008, 358(21): 2218-2230.

(**收稿**:2012-02-12;**修回**:2012-03-03)

(编辑 栾 嘉)

参考文献中英文作者名的著录方法

医学期刊的论文中,引用英文文献的比例很高,但有不少作者将英、美人的姓名搞错,以至用光盘核对时出现错姓、错名或姓名全错。英、美人姓名的习惯写法是:名-名-姓,"名"可以有1个、2个或3个,但"姓"只有1个。因此,从书籍或期刊中的姓名转录到文献时,要将次序调整为姓-名-名。姓是不可以简写的;"名"可以缩写,用第一个字母大写,不用缩写点。数据库在著录作者姓名时,已经调整为姓-名-名,可照录。

例如:John Quincy Public 写为 Public J Q。

本刊编辑部